{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:33:08Z","timestamp":1791181988817,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.leukres.2006.04.005","type":"journal-article","created":{"date-parts":[[2006,6,24]],"date-time":"2006-06-24T11:27:02Z","timestamp":1151148422000},"page":"1365-1370","source":"Crossref","is-referenced-by-count":53,"title":["Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit"],"prefix":"10.1016","volume":"30","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghi","family":"Manshouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2006.04.005_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2006.04.005_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000085561","article-title":"Systemic mastocytosis: bone marrow pathology, classification, and current therapies","volume":"114","author":"Pardanani","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2006.04.005_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.leukres.2006.04.005_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","article-title":"Chronic myeloid leukemia: a model for oncology","volume":"84","author":"Hehlmann","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2006.04.005_bib5","volume":"31","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2006.04.005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2006.04.005_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2006.04.005_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/cncr.21299","article-title":"AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells","volume":"104","author":"Verstovsek","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2006.04.005_bib9","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2006.04.005_bib10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2006.04.005_bib12","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3523.3523","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects","author":"Gleixner","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2424.2424","article-title":"BMS-354825 potently inhibits the kinase activity of kit activation loop mutations associated with systemic mastocytosis and induces apoptosis of mastocytosis cell lines","volume":"104","author":"Schittenhelm","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib15","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","article-title":"Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970","volume":"104","author":"Corbin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib16","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","article-title":"A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors","volume":"105","author":"Tanaka","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","article-title":"In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of kit","volume":"106","author":"Corbin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib18","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.04.005_bib19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2006.04.005_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood.V106.11.37.37","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph+ ALL)","volume":"106","author":"Kantarjian","year":"2005","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606001536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606001536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T19:37:09Z","timestamp":1627501029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212606001536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0145212606001536"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2006.04.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}